免疫检查点抑制剂（ICI）相关的心脏毒性。

Immune Checkpoint Inhibitors (ICIs)-Related Cardiotoxicity.

机构信息

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Department of Cardiology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Adv Exp Med Biol. 2020;1244:277-285. doi: 10.1007/978-3-030-41008-7_15.

DOI:10.1007/978-3-030-41008-7_15

PMID:32301022

Abstract

The growing success of immune checkpoint inhibitors (ICIs) has led to effectively treating several types of cancers. Even though their use has been associated with the development of cardiac adverse effects, which may decrease the overall survival in cancer patients. These cardiac toxicities are thought to be the result of targeting specific checkpoint proteins on normal myocardial cells leading to over stimulation of the immune system as well as secondary downstream off-target effects on normal tissue.Although cardiotoxicities related to immunotherapy are reportedly rare, they can be severe and associated with life-threatening conditions such as fulminant myocarditis, hemodynamic instability, and cardiac arrest.We will review the most commonly reported cardiovascular toxicities associated with ICIs and their management.

摘要

免疫检查点抑制剂（ICIs）的日益成功导致了多种癌症的有效治疗。尽管它们的使用与心脏不良事件的发展有关，这可能会降低癌症患者的总体生存率。这些心脏毒性被认为是由于针对正常心肌细胞上的特定检查点蛋白，导致免疫系统过度刺激以及对正常组织的二级下游脱靶效应。尽管与免疫疗法相关的心脏毒性据报道很少见，但它们可能很严重，并伴有危及生命的情况，如暴发性心肌炎、血流动力学不稳定和心脏骤停。我们将回顾与 ICIs 相关的最常见的心血管毒性及其管理。